No. 24
Time:9:30 AM, April 24, 2024 (Wednesday)
Location: Yifu Lecture Hall, North Basic Research Building
Host: Lin Mei
Chinese Institutes for Medical Research, Beijing
Speaker: Xiao-Jiang Li
Professor
Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University
Title: Use of monkey models to investigate brain diseases
Abstract:
Genetically modified animal models have been extensively utilized to explore the progression of age-related neurodegenerative conditions, including Alzheimer's (AD), Parkinson's (PD), Huntington's (HD) diseases, and Amyotrophic lateral sclerosis (ALS). These diseases share a common feature of age-related accumulation of misfolded proteins in the brain, a phenomenon replicated in various mouse models of neurodegenerative diseases. However, transgenic mouse models of AD, PD, and HD do not exhibit the pronounced neuronal loss or degeneration typically seen in patient brains. Discrepancies in pathology between transgenic mouse models and human brains may be attributed to species differences between small animals and humans. By utilizing CRISPR/Cas9 to express the disease genes in large animals such as monkeys, we can replicate typical neuropathological features in the brains of the larger animals. These results emphasize the significance of employing non-human primates to investigate the progression of significant brain disorders and their treatments.
Selected Papers:
Speaker: Shihua Li
Professor
Guangdong-Hongkong-Macau Institute of CNS Regeneration, Jinan University
Title: Huntington Disease Therapy by Targeting HTT
Abstract:
Huntington’s disease (HD) is caused by the abnormal expansion of CAG repeats in the huntingtin gene (HTT), leading to the production of the mutant huntingtin protein (mHTT) containing a polyglutamine sequence in its N-terminus. The pathogenic mechanisms driving HD are complex and not entirely understood. While mouse models carrying mutant HTT offer valuable insights into HD pathogenesis, many of these models do not exhibit the pronounced neurodegeneration typical of HD patients. We have established HD knock-in pigs that faithfully replicate selective neurodegeneration seen in HD. Employing gene therapy to eliminate the mutant gene in HD knock-in pigs can produce effective therapeutic outcomes. Additionally, we have developed a strategy to target mutant HTT using an intracellular antibody directed to the lysosome for degradation, demonstrating promising therapeutic effects on HD pathology.
Selected Papers: